FDA Drug Label
WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo, 2021
GLP-1 & MetabolicFDA ApprovedS
Semaglutide
Ozempic / Wegovy / Rybelsus
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 11
- Research grade
- S
- Experience
- 57
- Activity
- 38
Overall check-ins
Trackers & reports
Overview
About Semaglutide
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.
- Category
- GLP-1 & Metabolic
- Regulatory status
- FDA Approved
- Also known as
- Ozempic / Wegovy / Rybelsus
- Self-reports
- 26
Community
What 26 users report
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 96% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
122
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
117
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
32
0.2–0.4 mg
5
0.4–0.6 mg
4
0.6–1 mg
9
1–2 mg
33
2–3 mg
34
5+ mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 23 repeat reporters
Research
Cited research (8)
Source
FDA Drug Label
OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo, 2017
PubMed
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding et al., 2021
ClinicalTrials.gov
Semaglutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber et al., 2022
PubMed
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod et al., 2023
PubMed
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Wharton et al., 2022
PubMed
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff et al., 2023
Tools
Explore more
Explore
More ways to learn about Semaglutide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Semaglutide?
This page summarizes 26 anonymized self-reports from PeptIQ users who track Semaglutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Semaglutide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Semaglutide?
8 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Semaglutide safe to use?
This wiki does not assess safety or recommend use. Semaglutide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Semaglutide?
This wiki summarizes observational community reports and linked citations for Semaglutide. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Semaglutide for study-level context — not medical advice.
What is the legal status of Semaglutide?
Semaglutide is listed in PeptIQ as FDA Approved. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Semaglutide?
Safety data quality for Semaglutide varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Semaglutide?
This page links 8 indexed sources for Semaglutide. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.